Pfizer Biontech vaccine, the German company: “The second generation could arrive in mid-2021”

The day after the first vaccination in Britain and the announcement of approval by Canada, the German company Biontech, which developed the first approved vaccine with Pfizer, which has a declared efficacy of more than 90%, but must be kept at temperatures polar: says the second generation of the compound created to stop the coronavirus epidemic could be ready already in the second half of 2021.

BioNtech co-founder Ugur Sahin, in an interview with German television RTL, as reported by Bild, explained that the company is already working on the new vaccine. that can be transported at room temperatureinstead of the current -70 degrees, a condition that makes transportation logistically complicated. The vaccine, developed using the messenger RNA technique, is similar to that of the Modern company but can be stored at less demanding temperatures for those who will have to transport, store, distribute and administer it. It is not difficult to imagine that the “competition” of the American company for conservation has not stimulated German scientists.

The researcher also “believes that there will be sufficient doses of vaccines available for the summer for approximately 60-70% of the German population is immunized“. Biontech’s announcement comes on the day of the hacker attack on the European Medicines Agency (EMA). Documents related to the Pfizer-BioNtec anti-Covid vaccine were allegedly stolen during the cyberattack:” It is important to emphasize that neither neither BioNtech nor Pfizer systems were breached in connection with this incident and that we are not aware of the personal data that would have been breached. “.

Meanwhile, expectations are growing in the rest of Europe and in Italy to understand what will be the date for the start of vaccinations against Covid-19 in Italy. If there are no authorization problems, it will arrive as expected at the end of January and in any case after the EMA approval. The director of the agency explained that regarding BioNtech Pfizer the data received are positive in terms of efficacy and safetyAnd if there are no unforeseen events, the regulatory body “should probably speak on December 29.” Once the approval of Amsterdam is obtained, “the Italian validation will be almost immediate compared to the European one but, for now, there is no basis to indicate a specific day over another”, specifies Aifa, the Italian agency. The manufacturer will ship the doses to a single national hub, the military airport of Pratica di Mare, where they will be stored before being sent to the regions.